Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Ironwood Pharmaceuticals (IRWD) EBIAT (2016 - 2025)

Ironwood Pharmaceuticals' EBIAT history spans 16 years, with the latest figure at -$83.4 million for Q4 2025.

  • For Q4 2025, EBIAT fell 3797.65% year-over-year to -$83.4 million; the TTM value through Dec 2025 reached -$57.2 million, down 6596.14%, while the annual FY2025 figure was $24.0 million, 2629.2% up from the prior year.
  • EBIAT for Q4 2025 was -$83.4 million at Ironwood Pharmaceuticals, down from $40.0 million in the prior quarter.
  • Across five years, EBIAT topped out at $391.3 million in Q2 2021 and bottomed at -$1.1 billion in Q2 2023.
  • The 5-year median for EBIAT is $30.3 million (2022), against an average of -$19.2 million.
  • The largest YoY upside for EBIAT was 2844.07% in 2025 against a maximum downside of 3797.65% in 2025.
  • A 5-year view of EBIAT shows it stood at $41.4 million in 2021, then rose by 18.11% to $48.9 million in 2022, then tumbled by 103.57% to -$1.7 million in 2023, then skyrocketed by 229.28% to $2.3 million in 2024, then plummeted by 3797.65% to -$83.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's EBIAT are -$83.4 million (Q4 2025), $40.0 million (Q3 2025), and $23.6 million (Q2 2025).